tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Timothy Chiang, 59 are a BUY (92.19%), 3 are a HOLD (4.69%), 2 are a SELL (3.13%).
Analyst Timothy Chiang, currently employed at CAPITAL ONE, carries an average stock price target met ratio of 35.63% that have a potential upside of 14.67% achieved within 180 days.
Timothy Chiang’s has documented 160 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on IRWD, Ironwood Pharmaceuticals at 08-Aug-2024.
Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 6/15/2018. The price target of $120 was fulfilled within 4 days with a profit of $17.71 (17.31%) receiving and performance score of 43.28.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
4 months 9 days ago
(08-Aug-2024)
6/6 (100%)
$3.41 (15.79%)
263
Buy
$66
$23.76 (56.25%)
$71
4 months 9 days ago
(08-Aug-2024)
10/13 (76.92%)
$21.94 (49.80%)
337
Buy
$70
$27.76 (65.72%)
$44
1 years 4 months 22 days ago
(25-Jul-2023)
2/3 (66.67%)
$8.35 (13.54%)
105
Hold
$44
$1.76 (4.17%)
$40
1 years 7 months ago
(17-May-2023)
5/5 (100%)
$1.03 (2.40%)
86
Buy
$33
$-25.16 (-43.26%)
$24
2 years 9 months 7 days ago
(11-Mar-2022)
3/3 (100%)
$-1.3 (-3.79%)
375
Which stock is Timothy Chiang is most bullish on?
What Year was the first public recommendation made by Timothy Chiang?
